WuXi Biologics’ Shares Jump Amid Hopes U.S. Sanction Bill May Hit Wall

(Bloomberg) — Shares in WuXi Biologics Cayman Inc. have had the largest surge in 19 months on speculation a U.S. bill that can ban Chinese biotechnology companies from doing business may be excluded from the National Defense Authorization Act (NDAA).

The stock jumped 14% in Hong Kong, the most since November 2022. The biosecure bill — which seeks to bar biotech providers “of concern” with alleged ties to a foreign adversary — wasn’t added in the U.S. fiscal 2025 NDAA, a key step to becoming legally effective.